VectivBio AG is a clinical-stage biotechnology company focused on transformational therapeutics for rare diseases, spun out from Therachon in 2019. The company draws on the expertise of its founders to build a portfolio of rare disease medicines while advancing apraglutide for Short Bowel Syndrome.
Facts & figures
-
Type of organizationPublic company
-
Year of foundation2019
-
Number of employees in Switzerland10-19
